Rajesh P. Chavan
Aurangabad, MH, India
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications
Pharmacokinetics and Penetration of a Novel Pharmacodynamically Optimized, Carbapenem-Sparing Antibiotic, WCK 4282 (Cefepime/Tazobactam), into Epithelial Lining Fluid of Healthy, Lung-, and Thigh-Infected Neutropenic Mice.
Journal: Microbial drug resistance (Larchmont, N.Y.)
Published: September 11, 2025
Efficacy and safety of a 3-day once-daily regimen of oral nafithromycin in comparison to oral moxifloxacin for the treatment of community-acquired bacterial pneumonia in adults: a phase III, randomized, double-blind controlled trial.
Journal: The Lancet regional health. Southeast Asia
Published: April 15, 2025
Serum Pharmacokinetics and Bone Penetration of Novel Broad-Spectrum Anti-MRSA Agent Levonadifloxacin in Wistar Rats.
Journal: Microbial drug resistance (Larchmont, N.Y.)
Published: October 03, 2024
Cefepime pharmacodynamic targets against Enterobacterales employing neutropenic murine lung infection and in vitro pharmacokinetic models.
Journal: The Journal of antimicrobial chemotherapy
Published: May 06, 2022
WCK 4034: A promising oxazolidinone for treating gram positive infections.
Journal: Bioorganic & medicinal chemistry letters
Published: March 24, 2022
Simultaneous determination of novel β-lactamase inhibitor WCK 4234 and Meropenem in dog plasma by LC-MS/MS and its application to preclinical pharmacokinetic study.
Journal: Biomedical chromatography : BMC
Published: November 18, 2021
Assessment of the in vitro cytochrome P450 (CYP) inhibition potential of nafithromycin, a next generation lactone ketolide antibiotic.
Journal: Xenobiotica; the fate of foreign compounds in biological systems
Published: October 20, 2020
Preclinical safety evaluation of nafithromycin (WCK 4873) with emphasis on liver safety in rat and dog.
Journal: Regulatory toxicology and pharmacology : RTP
Published: September 10, 2020
Assessment of in vitro inhibitory effects of novel anti MRSA benzoquinolizine fluoroquinolone WCK 771 (levonadifloxacin) and its metabolite on human liver cytochrome P450 enzymes.
Journal: Xenobiotica; the fate of foreign compounds in biological systems
Published: April 15, 2020
Safety, tolerability and pharmacokinetics of oral nafithromycin (WCK4873) after single or multiple doses and effects of food on single-dose bioavailability in healthy adult subjects.
Journal: Antimicrobial agents and chemotherapy
Published: October 09, 2019
Levonadifloxacin, a Novel Broad-Spectrum Anti-MRSA Benzoquinolizine Quinolone Agent: Review of Current Evidence.
Journal: Drug design, development and therapy
Published: September 04, 2019
In Vivo Pharmacokinetic/Pharmacodynamic Targets of Levonadifloxacin against Staphylococcus aureus in a Neutropenic Murine Lung Infection Model.
Journal: Antimicrobial agents and chemotherapy
Published: May 04, 2019
Last Updated: 09/26/2026